Chemotherapy-induced peripheral neuropathy: A current review

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-limiting adverse effect in cancer patients.
• CIPN affects 30-40% of patients receiving neurotoxic chemotherapy, with significant inter-patient variability in severity.
• CIPN often presents as sensory neuropathy with pain, potentially leading to long-term morbidity in cancer survivors.

Purpose of the Study:

• To review the management of peripheral neuropathy in cancer patients.
• To discuss the clinical phenotypes of CIPN.
• To explore the pathomechanisms of neurotoxic chemotherapeutic agents.

Main Methods:

• Literature review of existing studies on CIPN.
• Analysis of clinical data regarding CIPN presentation and progression.
• Examination of preclinical and clinical data on neurotoxic chemotherapy mechanisms.

Main Results:

• CIPN is a prevalent complication with potential for long-term sequelae.
• The severity and presentation of CIPN can vary widely among patients.
• Understanding the pathomechanisms of specific agents is crucial for management.

Conclusions:

• The increasing survival rates in cancer will likely increase the prevalence and burden of CIPN.
• A comprehensive approach to peripheral neuropathy in cancer patients is warranted.
• Further research into the pathomechanisms of neurotoxic agents may inform better management strategies.